{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marcos-Villar L"],"funding":["Spanish State Research Agency","Instituto de Salud Carlos III","Fondo Europeo para el Desarrollo Regional (FEDER) the CERCA Programme/Generalitat de Catalunya"],"pagination":["2387906"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11313003"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) ag"],"journal":["Emerging microbes & infections"],"pubmed_title":["Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium."],"pmcid":["PMC11313003"],"funding_grant_id":["SGR 653","ICI20/00067","COV20/00214","SGR 615","PI18/00699","PID2020-117425RB-C22","FIS PI22/00814"],"pubmed_authors":["Sorzano COS","Esteban I","Perdiguero B","Sistere-Oro M","Cuesta B","Esteban M","Casasnovas JM","Sanchez-Cordon PJ","Zamora C","Astorgano D","Lopez-Bigas N","Alonso MJ","Thielemans K","Sin L","Gomez CE","Alvarez E","Plana M","Anthiya S","Franceschini L","Borrajo ML","Lopez-Bravo M","Marcos-Villar L","Gelpi JL","Garcia F","Meyerhans A","Lou G","Garcia-Arriaza J"],"additional_accession":[]},"is_claimable":false,"name":"Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.","description":"Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) ag","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-04-07T16:05:52.318Z","creation":"2024-11-05T16:10:50.075Z"},"accession":"S-EPMC11313003","cross_references":{"pubmed":["39087555"],"doi":["10.1080/22221751.2024.2387906"]}}